Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 23 Squamous Cell Carcinoma of Head and Neck 10 Melanoma 8 Lung Neoplasms 8 Neoplasms 7 Carcinoma 6 Skin Neoplasms 5 Neoplasm Metastasis 5 Carcinoma, Squamous Cell 5 Carcinoma, Basal Cell 5 Adenocarcinoma 5 Mouth Neoplasms 4 Head and Neck Neoplasms 4 Colonic Neoplasms 4 Carcinoma, Renal Cell 4 Urinary Bladder Neoplasms 3 Sarcoma 3 Oropharyngeal Neoplasms 3 Laryngeal Neoplasms 3 Carcinoma, Merkel Cell 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Rectal Neoplasms 2 Pancreatic Neoplasms 2 Mesothelioma, Malignant 2 Hemangiosarcoma 2 Colorectal Neoplasms 2 Carcinoma, Hepatocellular 2 Adrenocortical Carcinoma 2

Interventions

Carboplatin 7 Pemetrexed 6 osimertinib 5 Drug Therapy 5 tislelizumab 3 anlotinib 3 aflutinib 3 Radiotherapy 3 Radiosurgery 3 Paclitaxel 3 Cisplatin 3 toripalimab 2 pembrolizumab 2 camrelizumab 2 apatinib 2 Surgical Procedures, Operative 2 S 1 (combination) 2 HM781-36B 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 trilaciclib 1 surufatinib 1 sintilimab 1 rezivertinib 1 lenvatinib 1 icotinib 1 famitinib 1 envafolimab 1 dacomitinib 1 cemiplimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NSCLC × cemiplimab × Clear all

NCT06865339 2026-04-13

TRIPL

Montefiore Medical Center

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡